{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:33:02Z","timestamp":1790443982609,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"crossref","award":["23267"],"award-info":[{"award-number":["23267"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004007","name":"Instituto Nazionale di Fisica Nucleare","doi-asserted-by":"crossref","award":["BEAT-PRO"],"award-info":[{"award-number":["BEAT-PRO"]}],"id":[{"id":"10.13039\/501100004007","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study aims at merging the therapeutic effects associated to the inhibition of Carbonic Anhydrase IX (CAIX), an essential enzyme overexpressed by cancer cells including mesothelioma and breast cancer, with those ones brought by the application of Boron Neutron Capture Therapy (BNCT). This task was pursued by designing a sulfonamido-functionalised-carborane (CA-SF) that acts simultaneously as CAIX inhibitor and boron delivery agent. The CAIX expression, measured by Western blot analysis, resulted high in both mesothelioma and breast tumours. This finding was exploited for the delivery of a therapeutic dose of boron (&gt;\u200920\u00a0\u03bcg\/g) to the cancer cells. The synergic cytotoxic effects operated by the enzymatic inhibition and neutron irradiation was evaluated in vitro on ZL34, AB22 and MCF7 cancer cells. Next, an in vivo model was prepared by subcutaneous injection of AB22 cells in Balb\/c mice and CA-SF was administered as inclusion complex with a \u03b2-cyclodextrin oligomer. After irradiation with thermal neutrons tumour growth was evaluated for 25\u00a0days by MRI. The obtained results appear very promising as the tumour growth was definitively markedly lower in comparison to controls and the CAIX inhibitor alone. This approach appears promising and it call consideration for the design of new therapeutic routes to cure patients affected by this disease.<\/jats:p>","DOI":"10.1038\/s41598-020-76370-1","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T06:02:46Z","timestamp":1604642566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["In vitro and in vivo BNCT investigations using a carborane containing sulfonamide targeting CAIX epitopes on malignant pleural mesothelioma and breast cancer cells"],"prefix":"10.1038","volume":"10","author":[{"given":"Diego","family":"Alberti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Michelotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lanfranco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Protti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Deagostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Geninatti Crich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"key":"76370_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2015.10.019","volume":"98","author":"JA Kemp","year":"2016","unstructured":"Kemp, J. A., Shim, M. S., Heo, C. Y. & Kwon, Y. J. \u2018Combo\u2019 nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Adv. Drug Deliv. Rev. 98, 3\u201318 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"76370_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","volume":"15","author":"HE Barker","year":"2015","unstructured":"Barker, H. E., Paget, J. T. E., Khan, A. A. & Harrington, K. J. The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence. Nat. Rev. Cancer 15, 409\u2013425 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"76370_CR3","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.3390\/ijms18071586","volume":"18","author":"DA Senthebane","year":"2017","unstructured":"Senthebane, D. A. et al. The role of tumor microenvironment in chemoresistance: To survive, keep your enemies closer. Int. J. Mol. Sci. 18, 1586 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"76370_CR4","first-page":"127","volume":"111","author":"L Gatti","year":"2005","unstructured":"Gatti, L. & Zunino, F. Overview of tumor cell chemoresistance mechanisms. Methods Mol. Med. 111, 127\u2013148 (2005).","journal-title":"Methods Mol. Med."},{"key":"76370_CR5","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.bmc.2012.09.018","volume":"21","author":"AJ Kivel\u00e4","year":"2013","unstructured":"Kivel\u00e4, A. J. et al. Carbonic anhydrase IX in malignant pleural mesotheliomas: a potential target for anti-cancer therapy. Bioorg. Med. Chem. 21, 1483\u20131488 (2013).","journal-title":"Bioorg. Med. Chem."},{"key":"76370_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/978-94-007-7359-2_12","volume":"75","author":"NK Tafreshi","year":"2014","unstructured":"Tafreshi, N. K., Lloyd, M. C., Bui, M. M., Gillies, R. J. & Morse, D. L. Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases. Subcell. Biochem. 75, 221\u2013254 (2014).","journal-title":"Subcell. Biochem."},{"key":"76370_CR7","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1002\/med.21497","volume":"38","author":"CT Supuran","year":"2018","unstructured":"Supuran, C. T. et al. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one. Med. Res. Rev. 38, 1799\u20131836 (2018).","journal-title":"Med. Res. Rev."},{"key":"76370_CR8","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1042\/BCJ20190177","volume":"476","author":"MY Mboge","year":"2019","unstructured":"Mboge, M. Y. et al. A non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells. Biochem. J. 476, 1497\u20131513 (2019).","journal-title":"Biochem. J."},{"key":"76370_CR9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1517\/17460441.2015.1038235","volume":"10","author":"CT Supuran","year":"2015","unstructured":"Supuran, C. T. & Winum, J. Y. Designing carbonic anhydrase inhibitors for the treatment of breast cancer. Expert Opin. Drug Discov. 10, 591\u2013597 (2015).","journal-title":"Expert Opin. Drug Discov."},{"key":"76370_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ctrv.2012.08.004","volume":"39","author":"C Ward","year":"2013","unstructured":"Ward, C. et al. New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat. Rev. 39, 171\u2013179 (2013).","journal-title":"Cancer Treat. Rev."},{"key":"76370_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrd2467","volume":"7","author":"CT Supuran","year":"2008","unstructured":"Supuran, C. T. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov. 7, 168\u2013181 (2008).","journal-title":"Nat. Rev. Drug Discov."},{"key":"76370_CR12","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.4155\/fmc.11.69","volume":"3","author":"CT Supuran","year":"2011","unstructured":"Supuran, C. T. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Fut. Med. Chem. 3, 1165\u20131180 (2011).","journal-title":"Fut. Med. Chem."},{"key":"76370_CR13","doi-asserted-by":"publisher","first-page":"9560","DOI":"10.1021\/acs.jmedchem.9b00945","volume":"62","author":"B Gr\u00fcner","year":"2019","unstructured":"Gr\u00fcner, B. et al. Metallacarborane sulfamides: Unconventional, specific, and highly selective inhibitors of carbonic anhydrase IX. J. Med. Chem. 62, 9560\u20139575 (2019).","journal-title":"J. Med. Chem."},{"key":"76370_CR14","doi-asserted-by":"publisher","first-page":"13760","DOI":"10.1002\/anie.201307583","volume":"52","author":"J Brynda","year":"2013","unstructured":"Brynda, J. et al. Carborane-based carbonic anhydrase inhibitors. Angew. Chemie Int. Ed. 52, 13760\u201313763 (2013).","journal-title":"Angew. Chemie Int. Ed."},{"key":"76370_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2020.112460","volume":"200","author":"J Dvo\u0159anov\u00e1","year":"2020","unstructured":"Dvo\u0159anov\u00e1, J. et al. Sulfonamido carboranes as highly selective inhibitors of cancer-specific carbonic anhydrase IX. Eur. J. Med. Chem. 200, 1\u201313 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"76370_CR16","doi-asserted-by":"publisher","first-page":"389869","DOI":"10.1155\/2014\/389869","volume":"2014","author":"P Mader","year":"2014","unstructured":"Mader, P. et al. Carborane-based carbonic anhydrase inhibitors: insight into CAII\/CAIX specificity from a high-resolution crystal structure, modeling, and quantum chemical calculations. Biomed. Res. Int. 2014, 389869 (2014).","journal-title":"Biomed. Res. Int."},{"key":"76370_CR17","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1021\/cr2000866","volume":"111","author":"F Issa","year":"2011","unstructured":"Issa, F., Kassiou, M. & Rendina, L. M. Boron in drug discovery: Carboranes as unique pharmacophores in biologically active compounds. Chem. Rev. 111, 5701\u20135722 (2011).","journal-title":"Chem. Rev."},{"key":"76370_CR18","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.1021\/cr200038x","volume":"111","author":"M Scholz","year":"2011","unstructured":"Scholz, M. & Hey-Hawkins, E. Carbaboranes as pharmacophores: Properties, synthesis, and application strategies. Chem. Rev. 111, 7035\u20137062 (2011).","journal-title":"Chem. Rev."},{"key":"76370_CR19","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/tcr.201402100","volume":"15","author":"HS Ban","year":"2015","unstructured":"Ban, H. S. & Nakamura, H. Boron-based drug design. Chem. Rec. 15, 616\u2013635 (2015).","journal-title":"Chem. Rec."},{"key":"76370_CR20","doi-asserted-by":"publisher","first-page":"9396","DOI":"10.1021\/jacs.0c02228","volume":"142","author":"J Poater","year":"2020","unstructured":"Poater, J. et al. Too persistent to give up: Aromaticity in boron clusters survives radical structural changes. J. Am. Chem. Soc. 142, 9396\u20139407 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"76370_CR21","doi-asserted-by":"publisher","first-page":"12387","DOI":"10.1002\/ange.201407359","volume":"126","author":"J Poater","year":"2014","unstructured":"Poater, J., Sol\u00e0, M., Vi\u00f1as, C. & Teixidor, F. \u03c0 Aromaticity and Three-Dimensional Aromaticity: Two sides of the Same Coin?. Angew. Chemie 126, 12387\u201312391 (2014).","journal-title":"Angew. Chemie"},{"key":"76370_CR22","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1002\/chem.201705181","volume":"24","author":"M Couto","year":"2018","unstructured":"Couto, M. et al. Discovery of Potent EGFR Inhibitors through the Incorporation of a 3D-Aromatic-Boron-Rich-Cluster into the 4-Anilinoquinazoline Scaffold: Potential drugs for glioma treatment. Chem. A Eur. J. 24, 3122\u20133126 (2018).","journal-title":"Chem. A Eur. J."},{"key":"76370_CR23","doi-asserted-by":"publisher","first-page":"6555","DOI":"10.1016\/j.bmcl.2013.10.067","volume":"23","author":"K Ohta","year":"2013","unstructured":"Ohta, K., Ogawa, T., Kaise, A. & Endo, Y. Enhanced estrogen receptor beta (ER\u03b2) selectivity of fluorinated carborane-containing ER modulators. Bioorg. Med. Chem. Lett. 23, 6555\u20136558 (2013).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"76370_CR24","doi-asserted-by":"publisher","first-page":"899","DOI":"10.4155\/fmc-2016-0022","volume":"8","author":"A Deagostino","year":"2016","unstructured":"Deagostino, A. et al. Insights into the use of gadolinium and gadolinium\/boron-based agents in imaging-guided neutron capture therapy applications. Fut. Med. Chem. 8, 899\u2013917 (2016).","journal-title":"Fut. Med. Chem."},{"key":"76370_CR25","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.2174\/0929867325666180904105212","volume":"26","author":"Z Yinghuai","year":"2018","unstructured":"Yinghuai, Z. et al. The Current Status and Perspectives of Delivery Strategy for Boronbased Drugs. Curr. Med. Chem. 26, 5019\u20135035 (2018).","journal-title":"Curr. Med. Chem."},{"key":"76370_CR26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.4103\/0973-1482.176167","volume":"12","author":"H Mirzaei","year":"2016","unstructured":"Mirzaei, H. et al. Boron neutron capture therapy: Moving toward targeted cancer therapy. J. Cancer Res. Ther. 12, 520\u2013525 (2016).","journal-title":"J. Cancer Res. Ther."},{"key":"76370_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.apradiso.2013.11.109","volume":"88","author":"RL Moss","year":"2014","unstructured":"Moss, R. L. Critical review, with an optimistic outlook, on Boron Neutron Capture Therapy (BNCT). Appl. Radiat. Isot. 88, 2\u201311 (2014).","journal-title":"Appl. Radiat. Isot."},{"key":"76370_CR28","doi-asserted-by":"crossref","unstructured":"Sauerwein, W. A. G. Principles and roots of neutron capture therapy. In Neutron Capture Therapy: Principles and Applications 9783642313349, 1\u201316 (Springer, Berlin, 2012).","DOI":"10.1007\/978-3-642-31334-9_1"},{"key":"76370_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.radonc.2009.01.010","volume":"92","author":"M Suzuki","year":"2009","unstructured":"Suzuki, M. et al. Impact of accelerator-based boron neutron capture therapy (AB-BNCT) on the treatment of multiple liver tumors and malignant pleural mesothelioma. Radiother. Oncol. 92, 89\u201395 (2009).","journal-title":"Radiother. Oncol."},{"key":"76370_CR30","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.radonc.2008.06.009","volume":"88","author":"M Suzuki","year":"2008","unstructured":"Suzuki, M. et al. A novel concept of treatment of diffuse or multiple pleural tumors by boron neutron capture therapy (BNCT). Radiother. Oncol. 88, 192\u2013195 (2008).","journal-title":"Radiother. Oncol."},{"key":"76370_CR31","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3390\/molecules25040828","volume":"25","author":"F Ali","year":"2020","unstructured":"Ali, F., Hosmane, N. S. & Zhu, Y. Boron chemistry for medical applications. Molecules 25, 828 (2020).","journal-title":"Molecules"},{"key":"76370_CR32","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/cmdc.201700039","volume":"12","author":"D Alberti","year":"2017","unstructured":"Alberti, D. et al. Theranostic nanoparticles loaded with imaging probes and rubrocurcumin for combined cancer therapy by folate receptor targeting. ChemMedChem 12, 502\u2013509 (2017).","journal-title":"ChemMedChem"},{"key":"76370_CR33","doi-asserted-by":"publisher","first-page":"8479","DOI":"10.1002\/chem.201003741","volume":"17","author":"S Geninatti-Crich","year":"2011","unstructured":"Geninatti-Crich, S. et al. MRI-guided neutron capture therapy by use of a dual gadolinium\/boron agent targeted at tumour cells through upregulated low-density lipoprotein transporters. Chem. A Eur. J. 17, 8479\u20138486 (2011).","journal-title":"Chem. A Eur. J."},{"key":"76370_CR34","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.msec.2018.06.042","volume":"92","author":"O Icten","year":"2018","unstructured":"Icten, O. et al. Gadolinium borate and iron oxide bioconjugates: Nanocomposites of next generation with multifunctional applications. Mater. Sci. Eng. C 92, 317\u2013328 (2018).","journal-title":"Mater. Sci. Eng. C"},{"key":"76370_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jconrel.2018.04.043","volume":"280","author":"D Alberti","year":"2018","unstructured":"Alberti, D. et al. An innovative therapeutic approach for malignant mesothelioma treatment based on the use of Gd\/boron multimodal probes for MRI guided BNCT. J. Control. Rel. 280, 31\u201338 (2018).","journal-title":"J. Control. Rel."},{"key":"76370_CR36","first-page":"907","volume":"36","author":"M Sasai","year":"2016","unstructured":"Sasai, M. et al. Novel hyaluronan formulation enhances the efficacy of boron neutron capture therapy for murine mesothelioma. Anticancer Res. 36, 907\u2013912 (2016).","journal-title":"Anticancer Res."},{"key":"76370_CR37","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.apradiso.2015.10.009","volume":"106","author":"MA Gadan","year":"2015","unstructured":"Gadan, M. A. et al. Reprint of application of BNCT to the treatment of HER2+ breast cancer recurrences: Research and developments in Argentina. Appl. Radiat. Isot. 106, 260\u2013264 (2015).","journal-title":"Appl. Radiat. Isot."},{"key":"76370_CR38","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.nano.2014.12.004","volume":"11","author":"D Alberti","year":"2015","unstructured":"Alberti, D. et al. A theranostic approach based on the use of a dual boron\/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment. Nanomed. Nanotechnol. Biol. Med. 11, 741\u2013750 (2015).","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"76370_CR39","doi-asserted-by":"publisher","first-page":"9193","DOI":"10.1021\/ic800999y","volume":"47","author":"Y Li","year":"2008","unstructured":"Li, Y., Carroll, P. J. & Sneddon, L. G. Ionic-liquid-promoted decaborane dehydrogenative alkyne-insertion reactions: A new route to o-carboranes. Inorg. Chem. 47, 9193\u20139202 (2008).","journal-title":"Inorg. Chem."},{"key":"76370_CR40","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1021\/ic00036a043","volume":"31","author":"JG Wilson","year":"1992","unstructured":"Wilson, J. G., Anisuzzaman, A. K. M., Soloway, A. H. & Alam, F. Development of carborane synthons: Synthesis and chemistry of (aminoalkyl)Carboranes. Inorg. Chem. 31, 1955\u20131958 (1992).","journal-title":"Inorg. Chem."},{"key":"76370_CR41","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1002\/anie.201007992","volume":"50","author":"T Achard","year":"2011","unstructured":"Achard, T. et al. A regio- and diastereoselective platinum-catalyzed tandem [2+1]\/[3+2] cycloaddition sequence. Angew. Chemie Int. Ed. 50, 3552\u20133556 (2011).","journal-title":"Angew. Chemie Int. Ed."},{"key":"76370_CR42","doi-asserted-by":"publisher","first-page":"103324","DOI":"10.1016\/j.bioorg.2019.103324","volume":"93","author":"E Azzi","year":"2019","unstructured":"Azzi, E. et al. Design, synthesis and preliminary in-vitro studies of novel boronated monocarbonyl analogues of Curcumin (BMAC) for antitumor and \u03b2-amiloyd disaggregation activity. Bioorg. Chem. 93, 103324 (2019).","journal-title":"Bioorg. Chem."},{"key":"76370_CR43","first-page":"113","volume":"414","author":"S Bortolussi","year":"2018","unstructured":"Bortolussi, S. et al. Neutron flux and gamma dose measurement in the BNCT irradiation facility at the TRIGA reactor of the University of Pavia. Nucl. Instruments Methods Phys. Res. Sect. B Beam Interact. Mater. Atoms 414, 113\u2013120 (2018).","journal-title":"Res. Sect. B Beam Interact. Mater. Atoms"},{"key":"76370_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.taap.2016.12.017","volume":"316","author":"AA Abd-El Fattah","year":"2017","unstructured":"Abd-El Fattah, A. A., Darwish, H. A., Fathy, N. & Shouman, S. A. Carbonic anhydrase inhibition boosts the antitumor effects of Imatinib mesylate via potentiating the antiangiogenic and antimetastatic machineries. Toxicol. Appl. Pharmacol. 316, 123\u2013138 (2017).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"76370_CR45","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.21037\/jtd.2018.01.152","volume":"10","author":"L Lang-Lazdunski","year":"2018","unstructured":"Lang-Lazdunski, L. Malignant pleural mesothelioma: Some progress, but still a long way from cure. J. Thorac. Dis. 10, 1172\u20131177 (2018).","journal-title":"J. Thorac. Dis."},{"key":"76370_CR46","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3389\/fonc.2019.01519","volume":"9","author":"F Nicolini","year":"2020","unstructured":"Nicolini, F. et al. Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future. Front. Oncol. 9, 1519 (2020).","journal-title":"Front. Oncol."},{"key":"76370_CR47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1183\/09059180.00007014","volume":"24","author":"OD R\u00f8e","year":"2015","unstructured":"R\u00f8e, O. D. & Stella, G. M. Malignant pleural mesothelioma: History, controversy and future of a manmade epidemic. Eur. Respir. Rev. 24, 115\u2013131 (2015).","journal-title":"Eur. Respir. Rev."},{"key":"76370_CR48","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1002\/1521-3765(20011217)7:24<5261::AID-CHEM5261>3.0.CO;2-D","volume":"7","author":"S Aime","year":"2001","unstructured":"Aime, S. et al. High-relaxivity contrast agents for magnetic resonance imaging based on multisite interactions between a beta-cyclodextrin oligomer and suitably functionalized GdIII chelates. Chemistry 7, 5261\u20135269 (2001).","journal-title":"Chemistry"},{"key":"76370_CR49","doi-asserted-by":"publisher","first-page":"10940","DOI":"10.1021\/cr500081p","volume":"114","author":"G Crini","year":"2014","unstructured":"Crini, G. Review: A history of cyclodextrins. Chem. Rev. 114, 10940\u201310975 (2014).","journal-title":"Chem. Rev."},{"key":"76370_CR50","doi-asserted-by":"publisher","first-page":"110425","DOI":"10.1016\/j.colsurfb.2019.110425","volume":"183","author":"X Li","year":"2019","unstructured":"Li, X. et al. Micelles via self-assembly of amphiphilic beta-cyclodextrin block copolymers as drug carrier for cancer therapy. Colloids Surf. B. Biointerfaces 183, 110425 (2019).","journal-title":"Colloids Surf. B. Biointerfaces"},{"key":"76370_CR51","doi-asserted-by":"crossref","unstructured":"Kiyanagi, Y., Sakurai, Y., Kumada, H. & Tanaka, H. Status of accelerator-based BNCT projects worldwide. In AIP Conference Proceedings 2160 (American Institute of Physics Inc., 2019).","DOI":"10.1063\/1.5127704"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76370-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T17:35:19Z","timestamp":1670348119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76370-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["76370"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-76370-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]},"assertion":[{"value":"29 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19274"}}